Comanche Biopharma

Series-B+
comanchebiopharma.com Biotech & Healthcare Concord, United States Founded 2020 11-50
Total Funding $75M
Latest Round Undisclosed Series-B+
Last Announced Feb 26, 2025
Investors 6 Backers
Decision Makers 6 Verified

About Comanche Biopharma

Develops an investigational siRNA medicine for preterm preeclampsia.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Concord, United States
Year Founded 2020
Team Size 11-50
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website comanchebiopharma.com
Domain Registered Date Jul 9, 2020

Social & Network Presence

X / Twitter Profile @ComancheBio (38 followers) Created on May 2023
LinkedIn Corporate Not linked

Company Milestones & Timeline

5 Events
  1. Capital Raise

    Series-B+ announced

    startupintros.com

  2. Capital Raise

    Raised $75,000,000 · Series-B+

    startupintros.com

  3. Milestone

    X account created (@ComancheBio)

    38 followers

  4. Milestone

    Website domain registered

    comanchebiopharma.com

  5. Milestone

    Company founded

    Concord, United States

Investors & Backers

6
Atlas Venture
F-Prime Capital
GV
Lilly Asia Ventures
Longview Ventures
NEA

Funding History

2 Rounds
Series-B+ · Feb 26, 2025
Series-B+ · Jan 1, 2024

Founders & Leadership

5

Allison August

Chief Medical Officer

Work email & phone locked Unlock →

Mike Young

Founder

Work email & phone locked Unlock →

Richard Colvin

Global Head of Research and Development

Work email & phone locked Unlock →

Scott Johnson

Chief Executive Officer & Co-Founder

Work email & phone locked Unlock →

Thomas Scott Johnson

Founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts